DE60132169T2 - Humaner c1 inhibitor hergestellt in der milch transgener säugetiere - Google Patents

Humaner c1 inhibitor hergestellt in der milch transgener säugetiere Download PDF

Info

Publication number
DE60132169T2
DE60132169T2 DE60132169T DE60132169T DE60132169T2 DE 60132169 T2 DE60132169 T2 DE 60132169T2 DE 60132169 T DE60132169 T DE 60132169T DE 60132169 T DE60132169 T DE 60132169T DE 60132169 T2 DE60132169 T2 DE 60132169T2
Authority
DE
Germany
Prior art keywords
inhibitor
human
milk
human mammal
transgenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60132169T
Other languages
German (de)
English (en)
Other versions
DE60132169D1 (de
Inventor
Johannes Henricus Nuijens
Henricus Antonius Van Veen
Frank R. Pieper
Joris Jan Heus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharming Intellectual Property BV
Original Assignee
Pharming Intellectual Property BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property BV filed Critical Pharming Intellectual Property BV
Application granted granted Critical
Publication of DE60132169D1 publication Critical patent/DE60132169D1/de
Publication of DE60132169T2 publication Critical patent/DE60132169T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C2230/00—Aspects relating to animal feed or genotype
    • A23C2230/05—Milk or milk products from transgenic animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
DE60132169T 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere Expired - Lifetime DE60132169T2 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US17931000P 2000-01-31 2000-01-31
EP00200320 2000-01-31
EP00200320 2000-01-31
US179310P 2000-01-31
US18758000P 2000-03-07 2000-03-07
EP00200810 2000-03-07
US187580P 2000-03-07
EP00200810 2000-03-07
PCT/NL2001/000068 WO2001057079A2 (en) 2000-01-31 2001-01-31 C1 inhibitor produced in the milk of transgenic mammals

Publications (2)

Publication Number Publication Date
DE60132169D1 DE60132169D1 (de) 2008-02-14
DE60132169T2 true DE60132169T2 (de) 2008-12-11

Family

ID=56290105

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60132169T Expired - Lifetime DE60132169T2 (de) 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere
DE122011000002C Pending DE122011000002I1 (de) 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122011000002C Pending DE122011000002I1 (de) 2000-01-31 2001-01-31 Humaner c1 inhibitor hergestellt in der milch transgener säugetiere

Country Status (9)

Country Link
EP (1) EP1252184B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003521914A (cg-RX-API-DMAC7.html)
AT (1) ATE382635T1 (cg-RX-API-DMAC7.html)
CA (1) CA2398707C (cg-RX-API-DMAC7.html)
DE (2) DE60132169T2 (cg-RX-API-DMAC7.html)
DK (1) DK1252184T3 (cg-RX-API-DMAC7.html)
ES (1) ES2299473T3 (cg-RX-API-DMAC7.html)
PT (1) PT1252184E (cg-RX-API-DMAC7.html)
WO (1) WO2001057079A2 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
DE10112617A1 (de) * 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003301332B2 (en) * 2002-10-17 2008-06-12 Pharming Intellectual Property B.V. Protein modification
EP1947116B1 (en) 2003-02-10 2017-06-21 2-BBB Medicines B.V. Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
US7544853B2 (en) * 2003-05-16 2009-06-09 Pharming Intellectual Property B.V. C1 inhibitor with short half-life transient treatment
US8071532B2 (en) 2005-12-21 2011-12-06 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
FR2901796A1 (fr) * 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
LT3028716T (lt) 2006-10-10 2020-12-10 Regenesance B.V. Komplemento slopinimas nervų regeneracijos pagerinimui
JP5507555B2 (ja) * 2008-06-30 2014-05-28 チョ−エー・ファーム・カンパニー・リミテッド 豚のαS1カゼイン遺伝子、そのプロモーター、及びその用途
WO2010087702A1 (en) 2009-01-30 2010-08-05 Stichting Katholieke Universiteit TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2011034421A1 (en) 2009-09-16 2011-03-24 Stichting Het Nederlands Kanker Instituut Fra-1 target genes as drug targets for treating cancer
EP2305717A1 (en) 2009-09-21 2011-04-06 Koninklijke Nederlandse Akademie van Wetenschappen Inhibiting TNIK for treating colon cancer
EP2354245A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of hepatic PPAR- activity
EP2354244A1 (en) 2010-02-04 2011-08-10 Stichting Top Institute Food and Nutrition MBL2 as a marker of liver-specific insulin resistance
WO2012026820A2 (en) 2010-08-27 2012-03-01 Pantarhei Bioscience B.V. Immunotherapeutic method for treating prostate cancer
EP2465928A1 (en) 2010-12-16 2012-06-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Treatment of Th17-mediated diseases
EP2866826B1 (en) 2012-06-27 2025-08-06 Meiragtx UK II Limited Combination for treating an inflammatory disorder
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
ES2912396T3 (es) 2012-11-02 2022-05-25 Bioverativ Usa Inc Anticuerpos anti-C1s del complemento y uso de los mismos
DK2946206T3 (en) 2013-01-20 2019-04-15 Dyax Corp EVALUATION, ANALYSIS AND TREATMENT OF PKAL-MEDIATED DISORDERS
ME02865B (me) 2013-03-15 2018-04-20 Shire Viropharma Inc C1-inh kompozicije za upotrebu u prevenciji i liječenju naslednog angioedema (hae)
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP4212175A1 (en) 2015-04-06 2023-07-19 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
CN108463243B (zh) * 2015-11-19 2022-06-14 夏尔人类遗传性治疗公司 重组人c1酯酶抑制剂及其用途
IL326479A (en) 2016-10-12 2026-04-01 Bioverativ Usa Inc Anti-c1s antibodies and methods of use thereof
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
BR112020017626A2 (pt) 2018-02-28 2020-12-22 Pharming Intellectual Property B.V. Tratamento e prevenção de pré-eclâmpsia
US11754570B2 (en) 2019-04-16 2023-09-12 Takeda Pharmaceutical Company Limited Methods for quantitation of functional C1 esterase inhibitor (FC1-INH)
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー.ブイ. C1エステラーゼ阻害剤によるウイルス感染関連症状の治療
MA71249A (fr) 2022-06-24 2025-04-30 Bioverativ Usa Inc. Méthodes de traitement de maladies médiées par complément

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601034B1 (fr) * 1986-07-03 1989-11-17 Pasteur Institut Inhibiteur de l'activite de la c1-esterase plasmatique (c1-inhibiteur) et d'autres enzymes proteolytiques du groupe des proteases a serine, son procede de preparation, acides nucleiques codant pour cet inhibiteur, methodes de detection d'affections correlees aux defauts dudit inhibiteur a l'aide d'anticorps ou de sondes nucleotidiques et medicaments contenant ledit inhibiteur de synthese
WO1991006650A1 (en) * 1989-10-27 1991-05-16 Cetus Corporation C1 inhibitor muteins and uses thereof
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4227762A1 (de) * 1992-08-24 1994-03-03 Behringwerke Ag Verwendung eines Kallikrein-Inhibitors zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie bestimmter Krankheiten
US6713662B1 (en) * 1994-07-27 2004-03-30 Pharming Intellectual Property B.V. Production of collagen in the milk of transgenic mammals
GB9807464D0 (en) * 1998-04-07 1998-06-10 Pharming Bv Purification of human acid µ-glucosidase

Also Published As

Publication number Publication date
DK1252184T3 (da) 2008-02-04
CA2398707A1 (en) 2001-08-09
WO2001057079A3 (en) 2002-08-15
PT1252184E (pt) 2008-04-15
JP2003521914A (ja) 2003-07-22
DE122011000002I1 (de) 2011-05-05
ES2299473T3 (es) 2008-06-01
EP1252184A2 (en) 2002-10-30
DE60132169D1 (de) 2008-02-14
ATE382635T1 (de) 2008-01-15
WO2001057079A2 (en) 2001-08-09
CA2398707C (en) 2010-10-26
EP1252184B1 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
EP1252184B1 (en) Human c1 inhibitor produced in the milk of transgenic mammals
DE69933216T2 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
DE69133372T2 (de) Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
DE3752130T2 (de) Herstellung von peptiden
DE69533583T2 (de) Nicht humane, transgenische säugetiere mit sich entwickelnder neurologischer krankheit
US7067713B2 (en) C1 Inhibitor produced in the milk of transgenic non-human mammals
DE69027683T2 (de) Herstellung rekombinanter polypeptide durch rinder und transgene methoden
DE69233468T2 (de) Prüfung und modell für alzheimers-krankheit
DE69534295T4 (de) Fibrinogenproduktion in transgenen tieren
DE69332537T2 (de) Für kappa-casein kodierende dna, verfahren zur gewinnung des proteins und seine verwendung
DE69232310T2 (de) Expression von aktivem menschlichem Protein C im Milchdrüsengewebe transgener Tiere
DE69233109T2 (de) Transgene tiermodelle fur alzheimer-krankheit
DE69120146T2 (de) Erzeugung xenogener antikörper
DE69332609T2 (de) Long wap promotor zur expression des menschlichen proteins c in säugetieren
DE60004635T2 (de) Baff, dessen inhibitoren und dessen verwendung zur modulierung der b-zell-antwort
DE69929324T2 (de) TRANSGENE Mäuse MIT VERÄNDERTER APOLIPOPROTEIN E-EXPRESSION UND TESTVERFAHREN.
EP1565564A4 (en) STILK-STABILIZED ANTIBODIES PRODUCED IN MILK AND METHOD FOR THE MANUFACTURE THEREOF
US6210736B1 (en) Transgenically produced prolactin
US20050160483A1 (en) Transgenically produced decorin
AU2001259465A1 (en) Transgenically produced decorin
EP0451823A2 (de) DNA-Konstrukte zur Expression von Proteinen in der Milchdrüse transgener Säugetiere
DE60037397T2 (de) Expression von ausgeschiedenem, menschlichem alpha-fetoprotein in transgenen tieren
DE60037513T2 (de) Transgene hergestellte antithrombin iii und deren mutanten
DE69433745T2 (de) Modifizierte, verkürzte regulatoren des komplementsystems
AU784724B2 (en) C1 inhibitor produced in the milk of transgenic mammals

Legal Events

Date Code Title Description
R065 Request for grant of supplementary protection certificate validly filed

Free format text: PRODUCT NAME: CONESTAT ALFA IN ALLEN DEM SCHUTZ DES GRUNDPATENTS ZUGRUNDE LIEGENDEN FORMEN; AUTHORISATION NO/DATE: EU/1/10/641 20101028

Spc suppl protection certif: 122011000002

R067 Examining division decision granting supplementary protection certificate

Free format text: PRODUCT NAME: CONESTAT ALFA IN ALLEN DEM SCHUTZ DES GRUNDPATENTS ZUGRUNDE LIEGENDEN FORMEN; AUTHORISATION NO/DATE: EU/1/10/641 20101028

Spc suppl protection certif: 122011000002

R069 Supplementary protection certificate granted

Free format text: PRODUCT NAME: CONESTAT ALFA IN ALLEN DEM SCHUTZ DES GRUNDPATENTS ZUGRUNDE LIEGENDEN FORMEN; AUTHORISATION NO/DATE: EU/1/10/641 20101028

Spc suppl protection certif: 122011000002